Toleranzia has developed a technology portfolio for treatment of autoimmune diseases. The main project is directed towards myasthenia gravis, a nerve-muscle disease for which there is a large unmet need for improved medical treatment.
In addition to this indication, the technology portfolio has also been evaluated in type 1 diabetes, rheumatoid arthritis and multiple sclerosis; common autoimmune diseases for which positive treatment effects have been achieved in animal models.
News & press releases
27 September - 2017